BACK TO BACK LATEST NEWS, Official Website about ,all over the world latest news, Entertainment,Sports,Health,Fashion Hollywood,Bollywood ,Business,Latest Stories,Political news,Stock market news,and Hot news and more other topics
Novartis International AG said on Friday that its Sandoz division is abandoning an effort to gain U.S. regulatory approval for a biosimilar of rituximab, a medication used to treat certain cancer and rheumatoid arthritis.
0 comments:
Post a Comment